Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | PRCP | P42785 | 5/20 | 0.36 |
| ▸ | SGK1 | O00141 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL889123 | 0.94 | CYP3A4 (0.40) | NR1I2KCNH2PRCPCYP3A4CYP2C9 | |
| SCHEMBL888788 | 0.84 | HCRTR1 (0.40) | HCRTR1HCRTR2CYP11B2CYP2D6 | |
| SCHEMBL889124 | 0.84 | BRAF (0.38) | NR1I2KCNH2PRCPCYP3A4CYP2C9 | |
| SCHEMBL888955 | 0.82 | NR1I2 (0.53) | NR1I2KCNH2PRCPCYP3A4CYP2C9 | |
| SCHEMBL888977 | 0.79 | PRMT5 (0.43) | PRCPOPRK1HCRTR1HCRTR2 | |
| SCHEMBL12824451 | 0.78 | NR1I2 (0.35) | NR1I2KCNH2PRCPCYP3A4CYP2C9 | |
| SCHEMBL12810215 | 0.77 | CYP3A4 (0.53) | NR1I2KCNH2CYP3A4CYP2C9ABCB11 | |
| SCHEMBL889077 | 0.77 | PRMT5 (0.49) | PRCP | |
| SCHEMBL888919 | 0.76 | CYP3A4 (0.47) | NR1I2KCNH2CYP3A4CYP2C9ABCB11 | |
| SCHEMBL12755259 | 0.76 | KCNH2 (0.50) | KCNH2CYP3A4CYP2C9CYP1A2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759332-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20110064697-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110064697-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | NR1I2 353/4885KCNH2 3785/4885PRCP 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.